Apellis Pharmaceuticals (APLS) EBIAT: 2020-2025
Historic EBIAT for Apellis Pharmaceuticals (APLS) over the last 6 years, with Sep 2025 value amounting to $215.7 million.
- Apellis Pharmaceuticals' EBIAT rose 475.52% to $215.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.0 million, marking a year-over-year increase of 117.99%. This contributed to the annual value of -$197.9 million for FY2024, which is 62.57% up from last year.
- Latest data reveals that Apellis Pharmaceuticals reported EBIAT of $215.7 million as of Q3 2025, which was up 611.77% from -$42.2 million recorded in Q2 2025.
- Apellis Pharmaceuticals' EBIAT's 5-year high stood at $215.7 million during Q3 2025, with a 5-year trough of -$219.2 million in Q2 2021.
- Over the past 3 years, Apellis Pharmaceuticals' median EBIAT value was -$66.4 million (recorded in 2024), while the average stood at -$58.7 million.
- In the last 5 years, Apellis Pharmaceuticals' EBIAT slumped by 289.02% in 2021 and then skyrocketed by 475.52% in 2025.
- Apellis Pharmaceuticals' EBIAT (Quarterly) stood at -$147.9 million in 2021, then declined by 12.21% to -$166.0 million in 2022, then soared by 46.64% to -$88.6 million in 2023, then soared by 58.96% to -$36.4 million in 2024, then skyrocketed by 475.52% to $215.7 million in 2025.
- Its last three reported values are $215.7 million in Q3 2025, -$42.2 million for Q2 2025, and -$92.2 million during Q1 2025.